Trial · NCT02707484
the Efficiency of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation
NCT02707484, Phase 3, Completed, Shanghai Jiao Tong University School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. the Efficiency of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation. Trials, record NCT02707484. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02707484
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- the Efficiency of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation
- NCT number
- NCT02707484
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 150 participants, actual
- Lead sponsor
- Shanghai Jiao Tong University School of Medicine
- Conditions
- Gastrointestinal Vascular Malformation
- Interventions
- Thalidomide (100mg), Thalidomide (50mg), placebo
- First posted
- 2016-03-14
- Last updated
- 2023-06-23
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | effective response rate | First 1-year follow-up versus the 1-year Observation Period. | the proportion of patients with "effective treatment, patients with ≥50% reduction of numbers of bleeding episodes after treatment during the First 1-year follow-up versus the 1-year Observation Period. |
| Secondary | overall rate of cases with cessation of bleeding | First 1-year follow-up versus the 1-year Observation Period. | The overall rate of cases with cessation of bleeding without rebleeding during the First 1-year Follow-up Period. |
| Secondary | rate of cases requiring blood transfusion | First 1-year follow-up versus the 1-year Observation Period. | The rate of cases requiring blood transfusion during the First 1-year follow-up. |
| Secondary | rate of cases requiring hospitalizations due to bleeding | First 1-year follow-up versus the 1-year Observation Period. | The rate of cases requiring hospitalizations due to bleeding during the 1st 1-year follow-up |
| Secondary | change in the transfusion volume of red cell | First 1-year follow-up versus the 1-year Observation Period. | The change in the transfusion volume of red cell during the First 1-year Follow-up Period versus the Observation Period. |
| Secondary | change in average bleeding duration | First 1-year follow-up versus the 1-year Observation Period. | The change in average bleeding duration (days) during the First 1-year Follow-up Period versus the Observation Period. |
| Secondary | change in average hemoglobin level | First 1-year follow-up versus the 1-year Observation Period. | The change in average hemoglobin level (g/L) during the First 1-year Follow-up Period versus the Observation Period. |
| Secondary | change in yearly hospitalization times | First 1-year follow-up versus the 1-year Observation Period. | The change in yearly hospitalization times due to bleeding during the First 1-year Follow-up Period versus the Observation Period. |
| Secondary | change in average hospital stay | First 1-year follow-up versus the 1-year Observation Period. | The change in average hospital stay (days)due to bleeding during the First 1-year Follow-up Period versus the Observation Period. |
| Secondary | change in yearly bleeding episodes | First 1-year follow-up versus the 1-year Observation Period. | The change in yearly bleeding episodes during the First 1-year Follow-up Period versus the Observation Period. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02707484
GET https://conductscience.org/api/trials/v1/NCT02707484/registered